Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Genedrive PLC (GDR)

  Print      Mail a friend       Annual reports

Tuesday 14 November, 2017

Genedrive PLC

Distribution agreement with Sysmex Asia Pacific

RNS Number : 3708W
Genedrive PLC
14 November 2017


14 November 2017 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.


genedrive plc ("genedrive" or the "Company")

genedrive signs distribution agreement with Sysmex Asia Pacific Pte Ltd for HCV

Agreement extends global commercial coverage

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, today announces that it has signed a distribution agreement with Sysmex Asia Pacific Pte Ltd, a subsidiary of Sysmex Corporation, for its CE-marked Genedrive® HCV ID Kit and Genedrive® platform in the Asia Pacific region. This is the second agreement signed with a subsidiary of Sysmex Corporation, a world leader in clinical laboratory systemization and solutions, and follows the announcement on 16th October 2017 of a distribution agreement for the EMEA region with Sysmex Europe GmbH.

The agreement with Sysmex Asia Pacific follows the same structure as the agreement with Sysmex Europe, with genedrive retaining responsibility for product development, quality management and manufacturing, and Sysmex Asia Pacific being responsible for sales, marketing, customer support and distribution activities across the region. Working together, the companies will focus on securing the required regulatory approvals in individual territories across Asia. genedrive anticipates some initial traction during the 2017/2018 financial year, with a further ramp up in 2018/19 when regulatory milestones are met. genedrive has retained the rights over the Indian market.


David Budd, CEO of genedrive, commented: "We are extremely pleased to extend our commercial reach with Sysmex Asia Pacific as our commercial partner for our Genedrive® HCV assay. This agreement provides access to another important and very relevant global region for Genedrive® encompassing countries with a high HCV burden." 

Frank Buescher, President and CEO of Sysmex Asia Pacific, commented: "We are excited about this collaboration opportunity with genedrive and incorporating their HCV assay in our unique offering for Liver Disease management in the APAC region."

Genedrive® HCV ID Kit is a qualitative HCV RNA assay, designed for use in a decentralised testing environment to deliver actionable results within 90 minutes. It is performed on the Company's portable molecular diagnostics platform, Genedrive®.

The person responsible for the release of this announcement on behalf of the Company is Matthew Fowler, Chief Financial Officer.

- Ends -

For further details please contact:

genedrive plc

David Budd: CEO                                                                                                             +44 (0)161 989 0245

Matthew Fowler: CFO


Sysmex Asia Pacific Pte Ltd

Frank Buescher: President and Chief Executive Officer                                                

Carlum Shiu: Director, Regional Marketing and Scientific Affairs

Carol Low: Manager, Regional Corporate Marketing                                                +65 6221 3626


Peel Hunt LLP

James Steel                                                                                                                      +44 (0)207 418 8900

Oliver Jackson


Consilium Strategic Communications

Chris Gardner                                                                                                                  +44 (0)203 709 5700

Matthew Neal

Laura Thornton

[email protected] 



Notes to Editors


About genedrive plc


genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has received CE-IVD Certification and has been launched in Africa. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and Asia Pacific regions.


Further details can be found at: and 


About Sysmex Asia Pacific Pte Ltd

Sysmex Asia Pacific Pte Ltd, located in Singapore, is a subsidiary of the Sysmex Corporation from Kobe, Japan. From our Singapore office - we serve our affiliates, distributors and customers throughout South and Southeast Asia, and Oceania. Globally Sysmex Group employs more than 8000 staff, of whom 560 work in the Asia Pacific region.

Sysmex is the global leader in haematology and a renowned specialist in haemostasis and urinalysis. In Asia Pacific, our healthcare solutions include immunoassay and clinical chemistry. As our expertise in the interdependency of disease and medical disciplines grows, we are growing to introduce solutions in other pressing areas such as oncology, flow cytometry, liquid biopsy and essential healthcare, to resource-poor Asia Pacific regions. This is allowing us to deliver the clinical value that primary healthcare workers such as physicians, surgeons and other specialists demand to realise better diagnostics, treatment and monitoring, thereby improving the quality of care of their patients.

Everything we do is driven by a single mission: Shaping the advancement of healthcare.

For more information about Sysmex Asia Pacific Pte Ltd, please visit,


About Hepatitis C

Hepatitis C (HCV) is an international public health challenge, comparable to other major communicable diseases, including HIV, tuberculosis and malaria. It is estimated that 150-200 million people, or approximately 3% of the world's population, are living with chronic HCV, and more than 350,000 people die yearly from HCV-related diseases. In 2016, WHO published the first global health sector strategy on Hepatitis with a goal of eliminating viral hepatitis as a major public health threat by 2030. New oral, well-tolerated treatment regimens can achieve cure rates of over 90%, however, access to rapid, inexpensive and accurate diagnostics are a critical bottleneck that must be addressed to eradicate HCV.

This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t